[go: up one dir, main page]

MA20150269A1 - N- [4-(quinolin-4-yloxy) cyclohexyl(méthyl)](hétéro) arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments - Google Patents

N- [4-(quinolin-4-yloxy) cyclohexyl(méthyl)](hétéro) arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Info

Publication number
MA20150269A1
MA20150269A1 MA37700A MA37700A MA20150269A1 MA 20150269 A1 MA20150269 A1 MA 20150269A1 MA 37700 A MA37700 A MA 37700A MA 37700 A MA37700 A MA 37700A MA 20150269 A1 MA20150269 A1 MA 20150269A1
Authority
MA
Morocco
Prior art keywords
arylcarboxamides
quinolin
yloxy
medicaments
hetero
Prior art date
Application number
MA37700A
Other languages
English (en)
Other versions
MA37700B1 (fr
Inventor
Hermann Künzer
Benjamin Bader
Gimenez Hortensia Faus
Duy Nguyen
Silke Köhr
Martin Fritsch
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA20150269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA20150269A1 publication Critical patent/MA20150269A1/fr
Publication of MA37700B1 publication Critical patent/MA37700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

N- [4-(quinolin-4-yloxy) cyclohexyl(méthyl)](hétéro) arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
MA37700A 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments MA37700B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26
PCT/EP2013/063118 WO2014001247A1 (fr) 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Publications (2)

Publication Number Publication Date
MA20150269A1 true MA20150269A1 (fr) 2015-08-31
MA37700B1 MA37700B1 (fr) 2018-03-30

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37700A MA37700B1 (fr) 2012-06-26 2013-06-24 N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Country Status (40)

Country Link
US (1) US9428460B2 (fr)
EP (1) EP2864291B1 (fr)
JP (1) JP6181172B2 (fr)
KR (1) KR20150023880A (fr)
AP (1) AP3919A (fr)
AR (1) AR091565A1 (fr)
AU (1) AU2013283543B2 (fr)
BR (1) BR112014032538A2 (fr)
CA (1) CA2877786C (fr)
CL (1) CL2014003443A1 (fr)
CO (1) CO7170167A2 (fr)
CR (1) CR20140593A (fr)
CU (1) CU20140144A7 (fr)
CY (1) CY1118412T1 (fr)
DK (1) DK2864291T3 (fr)
DO (1) DOP2014000295A (fr)
EA (1) EA028063B1 (fr)
EC (1) ECSP14032516A (fr)
ES (1) ES2609455T3 (fr)
HR (1) HRP20161745T1 (fr)
HU (1) HUE032306T2 (fr)
IL (1) IL236146B (fr)
JO (1) JO3342B1 (fr)
LT (1) LT2864291T (fr)
MA (1) MA37700B1 (fr)
ME (1) ME02590B (fr)
MX (1) MX2014016054A (fr)
NZ (1) NZ703100A (fr)
PE (1) PE20150154A1 (fr)
PH (1) PH12014502869B1 (fr)
PL (1) PL2864291T3 (fr)
PT (1) PT2864291T (fr)
RS (1) RS55500B1 (fr)
SG (1) SG11201408254UA (fr)
SI (1) SI2864291T1 (fr)
TN (1) TN2014000532A1 (fr)
TW (1) TWI600646B (fr)
UA (1) UA115447C2 (fr)
UY (1) UY34881A (fr)
WO (1) WO2014001247A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164374A1 (fr) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20190004742A (ko) * 2016-05-04 2019-01-14 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001268040A1 (en) 2000-06-23 2002-01-08 Eli Lilly And Company Methods and compounds for inhibiting mrp1
KR100883731B1 (ko) 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
JP2006515014A (ja) 2003-01-30 2006-05-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ＰＫＣ−θのインヒビターとして有用な２，４−ジアミノピリミジン誘導体
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005094251A2 (fr) 2004-03-17 2005-10-13 Glaxo Group Limited Antagonistes du recepteur muscarinique a l'acetylcholine m3
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (fr) 2004-05-27 2005-12-15 Jack Saffron Coupelle pour aliments empechant l'infestation par des parasites
MX2007005590A (es) 2004-11-09 2007-05-24 Smithkline Beecham Corp Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
US20090240070A1 (en) 2006-02-06 2009-09-24 Showa Denko K.K. Whitening dermatological preparations
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (fr) 2006-12-01 2008-06-05 The University Of Sydney Composés moléculaires polycycliques
WO2009023655A1 (fr) 2007-08-16 2009-02-19 Boehringer Ingelheim International Gmbh Inhibiteurs de chymase à base de quinazolinedione
WO2009055053A2 (fr) * 2007-10-26 2009-04-30 The Regents Of The University Of California Composés de diarylhydantoïne
JP5699075B2 (ja) 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
EP2349328A1 (fr) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Méthodes de traitement du cancer
NZ597528A (en) 2009-07-21 2014-08-29 Gilead Sciences Inc Inhibitors of flaviviridae viruses
CA2773615A1 (fr) 2009-09-11 2011-03-17 Arwed Cleve Thiohydantoines a substitution heteroarylmethyle, en tant que medicaments anticancer
WO2012009649A1 (fr) 2010-07-16 2012-01-19 Anderson Gaweco Inhibiteurs mif et leurs utilisations

Also Published As

Publication number Publication date
JP6181172B2 (ja) 2017-08-16
EA201500039A1 (ru) 2015-06-30
MA37700B1 (fr) 2018-03-30
WO2014001247A1 (fr) 2014-01-03
SG11201408254UA (en) 2015-01-29
EP2864291B1 (fr) 2016-10-05
RS55500B1 (sr) 2017-05-31
IL236146B (en) 2018-05-31
PH12014502869A1 (en) 2015-02-23
PE20150154A1 (es) 2015-02-19
ES2609455T3 (es) 2017-04-20
BR112014032538A2 (pt) 2017-06-27
CA2877786A1 (fr) 2014-01-03
SI2864291T1 (sl) 2017-01-31
TWI600646B (zh) 2017-10-01
CN104684896A (zh) 2015-06-03
CY1118412T1 (el) 2017-06-28
UY34881A (es) 2014-01-31
EP2864291A1 (fr) 2015-04-29
AP3919A (en) 2016-11-30
IL236146A0 (en) 2015-02-01
HK1206346A1 (en) 2016-01-08
CO7170167A2 (es) 2015-01-28
TN2014000532A1 (en) 2016-03-30
US20150191431A1 (en) 2015-07-09
PH12014502869B1 (en) 2015-02-23
DK2864291T3 (en) 2017-01-16
AU2013283543A1 (en) 2015-01-29
JP2015521641A (ja) 2015-07-30
JO3342B1 (ar) 2019-03-13
ME02590B (fr) 2017-06-20
TW201400460A (zh) 2014-01-01
CL2014003443A1 (es) 2015-06-26
PL2864291T3 (pl) 2017-07-31
AR091565A1 (es) 2015-02-11
AU2013283543B2 (en) 2017-11-02
UA115447C2 (uk) 2017-11-10
HRP20161745T1 (hr) 2017-02-24
ECSP14032516A (es) 2015-12-31
NZ703100A (en) 2016-10-28
LT2864291T (lt) 2017-01-10
KR20150023880A (ko) 2015-03-05
MX2014016054A (es) 2015-04-10
CR20140593A (es) 2015-02-16
US9428460B2 (en) 2016-08-30
CU20140144A7 (es) 2015-08-27
AP2014008141A0 (en) 2014-12-31
PT2864291T (pt) 2017-01-06
EA028063B1 (ru) 2017-10-31
DOP2014000295A (es) 2015-01-31
HUE032306T2 (en) 2017-09-28
CA2877786C (fr) 2020-08-25

Similar Documents

Publication Publication Date Title
EP2802325A4 (fr) Composés anesthésiques et procédés d'utilisation afférents
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EP2747769A4 (fr) Iminothiazines 2-spiro-substituées et leur mono- et dioxydes en tant qu'inhibiteurs bace, compositions et leur utilisation
EP2908825A4 (fr) Composés de dioxyde de thiadiazine substitués tricycliques en tant qu'inhibiteurs de bace, compositions et leur utilisation
PH12019500176B1 (en) Heterocyclic compounds and ther uses
EP2694521A4 (fr) Composés de dioxyde de thiadiazine fusionnée à la pyrrolidine en tant qu'inhibiteurs de bace, compositions et leur utilisation
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
JO3817B1 (ar) تركيبة سائلة مستقرة ل " amg 416 " (فيلكالسيتيد)
MA20150269A1 (fr) N- [4-(quinolin-4-yloxy) cyclohexyl(méthyl)](hétéro) arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
CO7200262A2 (es) Nueva dosificación y formulación
EP2757110A4 (fr) Nouveau variant d'alpha 1-antitrypsine, et ses procédés de préparation et d'utilisation
MX2014014010A (es) Metabolitos de (1r-trans) -n - [[2- (2,3-dihidro-4-benzofuranilo) ciclopropilo] metilo] propanamida.
CY1119984T1 (el) Σταθεροποιημενη αμορφη μορφη αγομελατινης, μια μεθοδος για την παρασκευη της και φαρμακευτικες συνθεσεις που την περιεχουν
MX367436B (es) Antagonistas de los receptores de quimiocina.
IN2014DN07191A (fr)
UY34081A (es) Composición farmacéutica que comprende drotaverina
UY34320A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos.
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
TH1401007761A (th) N-[4-(ควิโนลิน-4-อิลอกซี)ไซโคลเฮกซิล(เมธิล)](เฮเทอโร)อะริลคาร์บอกซาไมด์ ในฐานะเป็นแอนโดรเจน รีเซฟเตอร์ แอนตาโกนิสท์, การผลิต และ การใช้ของสิ่งเหล่านั้นในฐานะเป็นผลิตภัณฑ์ซึ่งมีคุณสมบัติเป็นยา
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
MY163393A (en) Pharmaceutical formulations of telmisartan and process for preparing the same
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия
UY33953A (es) Triazina-oxadiazoles